Probiotics easier to market as drugs than foods: PRI

By Paul Gander

- Last updated on GMT

PRI members are looking for medical approvals for probiotic products as food laws tighten
PRI members are looking for medical approvals for probiotic products as food laws tighten

Related tags Medicine

The EU’s strict nutrition and health claims regulation (NHCR) which has barred all probiotic claims means 'living microorganism'-based products could be easier to bring to market as drugs, a 4-year-old French group has said.

“Given what we know about the current regulatory landscape, we can say it is much easier to market living organisms as medical drugs,” ​said Pharmabiotics Research Institute (PRI) coordinator Joseph Simmons, who emphasised that for his group 'living organisms' did not necesarily equate to probiotics, which is for the moment at least, a non-authorised marketing term in the EU's 28 member states.

“One reason for these regulatory challenges [with foods and supplements] is that it’s much more difficult to prove prevention in a healthy patient than it is to demonstrate a mechanism of action in a sick patient.”

The population problem

Since the European Food Safety Authority (EFSA) began issuing opinions on health claim submissions under the NHCR in 2008, it has become clear that data based on healthy populations holds more weight than medical-style research based on diseased populations, even if the agency does not rule out them out completely.

Professor Ambroise Martin, head of EFSA’s Panel on Dietetic Products Nutrition and Allergies (NDA), spoke of the position at the International Probiotics Association (IPA) bi-annual meeting in Athens in May.

He told attendees: “Take antibiotic associated diarrhea – no problem. We can assess that. The population does not have to be healthy. We have accepted IBS (Irritable Bowel Syndrome). We have no problem to be at the borderline. Sometimes it is very subtle.”

“I hope there will be a positive opinion.”

The fact that has not happened yet, along with the already established presence of probiotics in the medical field with Russia and former Soviet Union states being prime examples of markets where probiotic drugs are routinely prescribed by medical professionals for paediatric, gut, immune and other conditions, is fuelling further interest in probiotics as medicines.

PRI board member and president of the European Scientific League for Probiotics (ESLP) Jean-Pol Warzée added: “A key part of the PRI vision is to get specific strains recognised for medicalised applications.”

Regulatory road blocks


Simmons said PRI members were drawn from both the pharmaceuticals and food and supplements sectors but the European Medicines Agency (EMA) was becoming the more attractive option.

“For example, up to now, some living microorganisms have been registered as ‘medical devices’ in different EU states,” ​said PRI executive scientist Magali Cordaillat-Simmons, speaking of a sub-route within EU medicines law that has become increasingly popular – for the moment at least.

“But from 2017, under the new EU Medical Devices Directive, it will no longer be possible to register these products that way.”

The PRI has supported its members in compiling pharmabiotic 'scientific opinion requests' that go to the EMA.

PRI is an EU, French and regionally-backed ‘excellence cluster’, that in part acts as a point of collaboration between academics and industry players, both large and small.

PRI members include Lallemand, Sanofi, Bristol-Meyers Squibb, Merck, DuPont-Danisco, INRA, IPRAD, Lesaffre and Protexin.

A pharmabiotics-themed event​ will take place in place in Paris at the end of October.

Related news

Show more

Related products

show more

Unlock the business potential of the protein trend

Unlock the business potential of the protein trend

Content provided by Valio | 08-Feb-2024 | White Paper

Read our white paper to learn how to overcome taste and texture challenges in protein products — and how to commercialise the protein trend by making delicious...

Custom Microbiome Solutions for Dairy & Alt-Dairy Products

Custom Microbiome Solutions for Dairy & Alt-Dairy Products

Content provided by ADM: Innovation that Feeds the Future | 13-Oct-2023 | White Paper

Backed by clinical studies and perfect for use in dairy and alt-dairy applications alike, ADM’s Active Lifestyle probiotic blend, BPL1™ probiotic, and...

Consumers Want Dairy—and More!

Consumers Want Dairy—and More!

Content provided by ADM: Innovation that Feeds the Future | 06-Oct-2023 | White Paper

In the thriving dairy industry, you’re well aware of the surging demand for both dairy and non-dairy products.

Related suppliers

Follow us